Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Hempdocon Sep 24, 2020 11:06pm
177 Views
Post# 31618579

RE:Just Listened to AGM Kulkarni Presentation

RE:Just Listened to AGM Kulkarni Presentation

enriquesuave wrote: Both Dr Kulkarni and Dr Jewett sounded very optimistic for this technology.  Dr Jewett mentioned us very well placed competitively compared to other treatments and also praised the safety aspect versus other cancer treatments.  Dr Kulkarni mentioned that 2 of the patients who wer CR at 90 days were still CR at 6 months mark.  They must of have received 2nd treatment as well.IMO. They still don't have 6 months data for all patients and now that treatment is optimized, we should see even better as seemed to be the impression both doctors had.  So out of 15 patients for PH1 and PH2 who have received high dose, 5 are CR or 33%.  As Dr Jewett mentioned maximum bladder volume will be now used in optimization, so no  more undertreated patients hopefully. We are lucky to have 25% CR on these 12 patients given under treatment by an average of 75% which shows the treatment works extremely well when simply using the right protocol.  Dr Jewett also mentioned that the other investigators from the other sites were very excited about this technology.  Patients are being enrolled in all 4 sites let's hope we can treat 12-15 in next 5-6 months.  5 US sites expected to onboard Q4 as well as one more Canadian site.  All will be using Optimized procedure a lesson well learnt by now. All IMO



Thanks for sharing Enrique...

Re:  "Dr Kulkarni mentioned that 2 of the patients who wer CR at 90 days were still CR at 6 months mark."


There were 3 patients who had CR at 90 days, so 2/3 of these particular under-dosed patients remained CR at 6 months...not bad at all.

Re:   "
So out of 15 patients for PH1 and PH2 who have received high dose, 5 are CR or 33%."  


5/15 or 33% with a CR is pretty good, but when only 2/15 actually receive the proper/therapeutic dose....not bad at all : )


 

Bullboard Posts